Sickle cell disease (SCD) is the most common inherited blood disorder in the United States and has long been neglected by research funders and drug developers. Two gene therapies approved in December 2023 changed the science but not yet the access picture: each costs more than $2 million, requires intensive treatment at specialist centers and arrives with safety trade-offs.
Core Patient Information
What is sickle cell disease?
Sickle cell disease (SCD) is a group of inherited blood disorders in which red blood cells become rigid and crescent-shaped instead of flexible and round. The altered cells break down early, causing chronic anemia, and they can block small blood vessels, causing sudden pain and damage to organs. The condition is caused by a mutation in the HBB gene, which encodes part of hemoglobin.
About 100,000 people in the United States have SCD, most of them African American, and an estimated 20 million people worldwide are affected. Symptoms usually begin in early childhood and vary widely between individuals. Because the disease damages the spleen, brain, lungs and kidneys over time, it is a lifelong condition that requires coordinated care, and it has historically carried a heavy burden of emergency visits, hospital stays and shortened life expectancy.
What causes sickle cell disease?
SCD is caused by a single-letter change in the HBB gene on chromosome 11, which alters beta-globin, one of the two protein chains in adult hemoglobin. The resulting abnormal hemoglobin, called hemoglobin S, can stick together in long strands when oxygen levels fall, which distorts the red blood cell into a sickle shape. Because both copies of the gene must carry the mutation for a person to have the disease, it is inherited in an autosomal recessive pattern.
The mutation spread in regions where malaria was common because carriers have some protection from severe malaria, which is why the disease is most prevalent among people with ancestry from sub-Saharan Africa, the Mediterranean, the Middle East and India. Nothing a parent does during pregnancy causes SCD, and it is not contagious. The most severe forms are hemoglobin SS disease and sickle beta-zero thalassemia.
What are the symptoms of sickle cell disease?
The hallmark symptom is episodes of severe pain, but the disease has many other effects. Chronic hemolytic anemia causes fatigue, pallor and sometimes jaundice. Swelling of the hands and feet can be an early sign in infants. Children are vulnerable to serious bacterial infections because the spleen is damaged, and infection and stroke are major complications.
Other problems include acute chest syndrome, a lung complication with chest pain, cough and fever, delayed growth and puberty, vision problems, leg ulcers, kidney damage and avascular necrosis of the hip. By adulthood many patients live with chronic pain and organ damage. Severity is highly variable: some people have few crises, while others are hospitalized repeatedly. Because symptoms can escalate quickly, fever in a child with SCD, chest pain, weakness on one side of the body or severe headache requires urgent medical attention.
What is a sickle cell crisis?
A sickle cell crisis, formally a vaso-occlusive crisis (VOC), is a sudden episode of severe pain that occurs when sickled red blood cells block blood flow in small vessels and deprive tissue of oxygen. Pain often affects the back, chest, abdomen, arms and legs and can last hours to days. It is the most common reason people with SCD seek emergency care. Pain crises are the most common and distinctive manifestation of the disease.
Other crises include acute chest syndrome, splenic sequestration, in which blood pools in the spleen, and aplastic crisis, often triggered by parvovirus infection. Treatment involves prompt pain relief, fluids and treatment of any trigger or complication; severe cases require hospitalization. Delays in analgesia have been a persistent complaint, and NPR reported that patients often face discrimination and poor care in emergency departments.
What triggers a sickle cell crisis?
Crises can occur without any obvious cause, but common triggers include temperature changes, stress, dehydration and high altitude, which promote sickling by lowering oxygen or concentrating blood. Infections, especially viral illnesses, are another frequent trigger, as are menstruation, alcohol and strenuous exercise in some patients. Practical prevention measures include staying well hydrated, dressing for temperature extremes, avoiding sudden cold exposure such as swimming in cold water, treating infections early and keeping up with vaccines and preventive antibiotics in children.
Disease-modifying treatments such as hydroxyurea, L-glutamine and crizanlizumab reduce the frequency of crises for some patients, and gene therapies aim to eliminate them. Because triggers vary, many patients keep a diary to identify their own patterns and discuss them with a hematologist. Anyone with pain that is not controlled by their usual plan, or with fever, should seek emergency care.
What is the difference between sickle cell trait and sickle cell disease?
People with sickle cell trait carry one copy of the sickle mutation and one normal HBB gene, whereas people with sickle cell disease carry two altered copies. Trait usually causes no health problems, and carriers are sometimes called sickle cell carriers. Disease, by contrast, causes anemia, pain crises and organ damage. One reference notes that trait does not cause health problems unless a person is exposed to extreme conditions such as high altitude or dehydration, when some symptoms can appear.
A person with trait can still pass the mutation to children. When both parents carry trait, each pregnancy has a 25% chance of a child with SCD, a 50% chance of a child with trait and a 25% chance of a child with neither. Newborn screening and carrier testing identify trait, and genetic counseling is recommended for couples who both carry it.
Is sickle cell disease inherited?
Yes. SCD is inherited in an autosomal recessive pattern, which means a child must receive a sickle mutation from both parents. Parents are usually carriers who have trait and no symptoms, which is why the disease can seem to appear unexpectedly in a family. If both parents carry the sickle mutation, each pregnancy carries a 25% chance of SCD. Children can also have forms of SCD when one sickle mutation is paired with another abnormal beta-globin variant, such as hemoglobin C or beta thalassemia.
Because both copies of the gene must carry the mutation, siblings of a patient may or may not be affected. Newborn screening programs in the U.S. detect SCD at birth so that preventive antibiotics and vaccines can begin in infancy. Prenatal testing and preimplantation genetic testing are available to couples who are at risk and want that information. Genetic counseling helps families understand their options.
What is the life expectancy for someone with sickle cell disease?
Life expectancy is substantially shorter than in the general population. A research summary reported by GoodRx states that in the United States it is at least 22 years shorter for people with SCD. Historical figures cited by NPR and KFF Health News showed life expectancy of 42 for men and 48 for women in 1994 and 38 and 42 in 2005, a decline linked to falling funding and clinic closures.
Specialty centers report better outcomes: clinics like Elliott Vichinsky's have increased life expectancy well into the 60s for patients under comprehensive care. Newborn screening, penicillin prophylaxis, vaccination, hydroxyurea and stroke screening in children have markedly improved survival in childhood, so the main gap now opens in adulthood. Averages hide wide variation: genotype, access to specialist care and insurance coverage shape outcomes, and newer therapies may change the picture over time.
What treatments are available for sickle cell disease?
Standard care includes hydroxyurea, which raises fetal hemoglobin, L-glutamine, crizanlizumab and regular blood transfusions for selected patients, along with pain management, infection prevention and screening for complications. Treatment may involve pain management, blood transfusions and antibiotics, and bone marrow transplantation can cure SCD but requires a matched donor, limiting its use. One drug, Pfizer's Oxbryta, was voluntarily withdrawn worldwide in September 2024 after postmarketing data showed more crises and deaths than placebo; the drug had won accelerated approval in 2019 for patients 12 and older and in 2021 for children 4 to 11.
Two gene therapies were approved on December 8, 2023: Casgevy, a CRISPR gene-editing therapy from Vertex and CRISPR Therapeutics, and Lyfgenia, a gene-addition therapy now marketed by Genetix Biotherapeutics, formerly bluebird bio. Both are one-time treatments that use a patient's own stem cells. Vertex says Casgevy reduces or eliminates vaso-occlusive crises and has been approved for children as young as two.
Market and Controversy Information
Why do sickle cell gene therapies cost more than $2 million?
Casgevy lists at $2.2 million and Lyfgenia at $3.1 million per patient. Each dose is manufactured individually from the patient's own stem cells, which are collected, modified in a laboratory and returned after chemotherapy, a complex process with high fixed costs for a small population. Developers and advocates argue that one-time cures can offset lifelong costs; the Sickle Cell Disease Association of America notes that savings in lifelong care may exceed the one-time cost.
ICER estimated that an appropriate price for Casgevy would be between $1.35 million and $2.05 million. Payers have raised concerns about small trials and limited long-term data. A hematologist at UCHealth predicted that even after negotiations the cost would still fall between $1 million and $1.5 million. The list prices are therefore contested, but they are not unusual for gene therapies.
Are Casgevy and Lyfgenia accessible to the patients who need them most?
Not easily. Eligibility is restricted: the therapies are approved for people with SS and sickle beta-zero genotypes, but not SC disease, and patients must be healthy enough for chemotherapy. Treatment takes place only at specialized centers. The patient population is disproportionately Black and low-income, and between 50% and 60% of people with SCD have Medicaid, so state coverage decisions are decisive.
Uptake has been gradual: Vertex reported Casgevy revenue of $76 million in the second quarter of 2026, up 151% from a year earlier but small compared with the eligible population. Casgevy is approved in 39 countries across North America, Europe and the Middle East, a footprint that excludes most of sub-Saharan Africa, where much of the global burden lies. Families also face weeks of hospitalization and time away from work.
Can Medicaid programs afford sickle cell gene therapies?
Individually, each treatment represents a very large expense for a state budget, which is why the federal government intervened. The CMS Cell and Gene Therapy Access Model lets CMS negotiate outcomes-based agreements with manufacturers on behalf of states. According to CMS, 32 states, the District of Columbia and Puerto Rico, covering 84% of Medicaid beneficiaries with SCD, are participating, and both Vertex and Genetix have signed agreements.
What are the safety risks of the chemotherapy and genetic modification used in sickle cell gene therapy?
Both therapies require chemotherapy to clear existing bone marrow before modified cells are infused. Axios reported that this step may not be appropriate for older or frail patients, and the Sickle Cell Disease Association of America lists infertility, unknown organ damage and unknown long-term effects among the concerns. Lyfgenia's label carries a boxed warning about cancer risk, and both therapies require long-term follow-up. Conditioning chemotherapy typically means an extended hospital stay and a temporary loss of blood-forming cells, which raises infection risk.
Casgevy's gene editing raises a theoretical concern about unintended edits, and patients for both products are tracked in long-term risk studies. Because infertility is a recognized concern, discussing fertility preservation before treatment is prudent. Vertex says it is advancing preclinical assets for gentler conditioning, which could broaden eligibility. For now, patients must weigh the potential of fewer or no crises against these upfront risks.
Why has sickle cell disease historically received less funding, research and clinical attention than comparable conditions?
Patients and experts quoted by NPR link the neglect to the disease's racial and socioeconomic profile. A cross-sectional study in JAMA Network Open found that from 2008 through 2018, federal funding per person was $2,807 for cystic fibrosis versus $812 for sickle cell disease, with more research articles and drug approvals for cystic fibrosis. An earlier study cited by NPR found cystic fibrosis received seven to 11 times more funding per patient, and that the FDA approved five CF drugs between 2010 and 2013.
Philanthropic funding also differs sharply, with GoodRx's summary citing roughly $100 per person for sickle cell versus about $7,700 for cystic fibrosis. NPR reported that funding waned and specialty clinics closed after the 1990s. The study authors concluded that disparities may be associated with reduced research productivity and drug development. The same study found that the number of clinical trials was similar, suggesting the gap lay in funding and approvals rather than study counts.
Why are sickle cell gene therapies difficult to deliver outside specialist treatment centers?
Treatment is a multistep process: stem cells must be collected, often over several apheresis sessions, shipped for modification, and returned after a conditioning regimen that requires an extended stay. Under the CMS model, administration is for inpatients, and patients must be treated at CMS-designated centers enrolled in the CIBMTR registry.
Only a limited number of hospitals have the transplant expertise, intensive care capacity and cell-processing logistics to do this, and adult sickle cell expertise is scarce: NPR noted that one California clinic was one of only three places in the state offering specialized services for adults. Patients may need to travel to a distant center for extended stays. Vertex says approval of Casgevy in children as young as two means about 5,500 more patients with SCD or TDT may be eligible, growth that treatment centers will need to absorb.
How big is the sickle cell market, who are the key players and what is the outlook?
The market is small by revenue but growing. Casgevy generated $119 million in the first half of 2026, including $76 million in the second quarter, and Vertex expects at least $500 million in 2026 revenue from Casgevy and its pain drug Journavx combined. FDA approval for children aged two and older came in 53 days. CRISPR Therapeutics shares in Casgevy, and Genetix Biotherapeutics, formerly bluebird bio, markets Lyfgenia.
The market has also seen setbacks: Pfizer told the FDA on July 31, 2026 that it is voluntarily withdrawing the NDAs for Oxbryta. Outlook depends on access reforms, durable outcomes data and simpler delivery. Researchers are working on in-vivo gene editing that would avoid stem cell collection, and on gentler conditioning. Whether the therapies reach most patients, rather than a small minority, is the central question for the next decade.